Respiratory syncytial virus is the leading cause of lower respiratory tract infection among infants. RSV is a priority for vaccine development. In this study, we investigate the potential effectiveness of a two-vaccine strategy aimed at mothers-to-be, thereby boosting maternally acquired antibodies of infants, and their household cohabitants, further cocooning infants against infection. We use a dynamic RSV transmission model which captures transmission both within households and communities, adapted to the changing demographics and RSV seasonality of a low-income country. Model parameters were inferred from past RSV hospitalisations, and forecasts made over a 10-year horizon. We find that a 50% reduction in RSV hospitalisations is possible if the maternal vaccine effectiveness can achieve 75 days of additional protection for newborns combined with a 75% coverage of their birth household co-inhabitants (~7.5% population coverage).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556875 | PMC |
| http://dx.doi.org/10.7554/eLife.47003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons.
JAMA
December 2024
Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Epidemiological Characteristics of Pathogens in Bronchoalveolar Lavage Fluid in Children With Lower Respiratory Tract Infections: A Retrospective Analysis.
Pediatr Pulmonol
January 2025
Department of Pediatrics, Fu Yang People's Hospital, Fuyang, China.
Background: The COVID-19 pandemic has significantly altered the etiological spectrum and epidemiological characteristics of pediatric respiratory diseases, and a profound understanding of these changes is crucial for guiding clinical treatment. The purpose of this study is to analyze the etiological patterns and epidemiological features of pathogens in bronchoalveolar lavage fluid (BALF) from children with pediatric lower respiratory tract infections (LRTIs) after the COVID-19 pandemic, with the aim of providing effective therapeutic evidence for clinical practice.
Methods: This study enrolled pediatric patients diagnosed with LRTIs who were treated and underwent BALF pathogen detection at our hospital from June 1, 2023, to June 1, 2024.
Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection.
Can Commun Dis Rep
January 2025
Public Health Agency of Canada, Ottawa, ON.
Background: Availability of new vaccines for adults has increased interest in understanding Canada's respiratory syncytial virus (RSV) burden in older adults and adults considered at high risk of severe infection.
Objective: To characterize the burden of RSV disease in Canada by joint analysis of the published literature and hospitalization data from a healthcare administrative database.
Methods: Electronic databases of published literature were searched to identify studies and systematic reviews reporting data on outpatient visits, hospitalizations, intensive care unit (ICU) admissions and deaths associated with RSV infection in adults.
Profiling epithelial viral receptor expression in amniotic membrane and nasal epithelial cells at birth.
Placenta
December 2024
Telethon Kids Institute, Wal-yan Respiratory Research Centre, Perth, 6009, Western Australia, Australia.
Introduction: Children with wheeze and asthma present with airway epithelial vulnerabilities, such as impaired responses to viral infection. It is postulated that the in utero environment may contribute to the development of airway epithelial vulnerabilities. The aims of the study were to establish whether the receptors for rhinovirus (RV), respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are expressed in the amniotic membrane and whether the pattern of expression is similar to newborn nasal epithelium.
View Article and Find Full Text PDFAttitude to RSV Vaccination Among a Cohort of Pregnant Women in Jordan: A Cross-Sectional Survey Study.
Health Sci Rep
January 2025
Department of Obstetrics & Gynecology, School of Medicine The University of Jordan Amman Jordan.
Background And Aims: The recently approved maternal vaccination against respiratory syncytial virus (RSV) can reduce its burden among infants. However, vaccine hesitancy/resistance can undermine the beneficial impact of RSV vaccination. The aim of this study was to assess the willingness of pregnant women in Jordan to receive RSV vaccination and its associated determinants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!